Benzinga | Jan 18, 2022 09:39AM EST

HC Wainwright & Co. Maintains Buy on Taro Pharmaceutical Indus, Lowers Price Target to $75

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Taro Pharmaceutical Indus (NYSE:TARO) with a Buy and lowers the price target from $82 to $75.